Dynamics of viral DNA shedding and culture viral DNA positivity in different clinical samples collected during the 2022 mpox outbreak in Lombardy, Italy
- PMID: 38556220
- DOI: 10.1016/j.tmaid.2024.102698
Dynamics of viral DNA shedding and culture viral DNA positivity in different clinical samples collected during the 2022 mpox outbreak in Lombardy, Italy
Abstract
Background: Mpox virus (MPXV) has recently spread outside of sub-Saharan Africa. This large multicentre study was conducted in Lombardy, the most densely populated Italian region accounting for more than 40% of Italian cases. The present study aims to: i) evaluate the presence and the shedding duration of MPXV DNA in different body compartments correlating the MPXV viability with the time to onset of symptoms; ii) provide evidence of MPXV persistence in different body compartment as a source of infection and iii) characterize the MPXV evolution by whole genome sequencing (WGS) during the outbreak occurred in Italy.
Material and methods: The study included 353 patients with a laboratory-confirmed diagnosis of MPXV infection screened in several clinical specimens in the period May 24th - September 1st, 2022. Viral isolation was attempted from different biological matrices and complete genome sequencing was performed for 61 MPXV strains.
Results: MPXV DNA detection was more frequent in the skin (94.4%) with the longest median time of viral clearance (16 days). The actively-replicating virus in cell culture was obtained for 123/377 (32.6%) samples with a significant higher viral quantity on isolation positive samples (20 vs 31, p < 0.001). The phylogenetic analysis highlighted the high genetic identity of the MPXV strains collected, both globally and within the Lombardy region.
Conclusion: Skin lesion is gold standard material and the high viral load and the actively-replicating virus observed in genital sites confirms that sexual contact plays a key role in the viral transmission.
Keywords: Molecular epidemiology; Mpox virus; Multiple samples; Next generation sequencing; Re-Emerging virus.
Copyright © 2024. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Clinical presentation, viral shedding, and neutralizing antibody responses of mpox cases in South Korea: Single center experience.J Clin Virol. 2024 Aug;173:105692. doi: 10.1016/j.jcv.2024.105692. Epub 2024 May 14. J Clin Virol. 2024. PMID: 38830304
-
Role of Direct Sexual Contact in Human Transmission of Monkeypox Virus, Italy.Emerg Infect Dis. 2024 Sep;30(9):1829-1833. doi: 10.3201/eid3009.240075. Epub 2024 Aug 10. Emerg Infect Dis. 2024. PMID: 39127126 Free PMC article.
-
Profiling of viral load, antibody and inflammatory response of people with monkeypox during hospitalization: a prospective longitudinal cohort study in China.EBioMedicine. 2024 Aug;106:105254. doi: 10.1016/j.ebiom.2024.105254. Epub 2024 Jul 23. EBioMedicine. 2024. PMID: 39043012 Free PMC article.
-
Review of virological methods for laboratory diagnosis and characterization of monkeypox virus (MPXV): lessons learned from the 2022 Mpox outbreak.Acta Dermatovenerol Alp Pannonica Adriat. 2024 Mar;33(1):23-35. Acta Dermatovenerol Alp Pannonica Adriat. 2024. PMID: 38179904 Review.
-
Monkeypox outbreak: Wastewater and environmental surveillance perspective.Sci Total Environ. 2023 Jan 15;856(Pt 2):159166. doi: 10.1016/j.scitotenv.2022.159166. Epub 2022 Oct 3. Sci Total Environ. 2023. PMID: 36202364 Free PMC article. Review.
Cited by
-
MPXV DNA kinetics in bloodstream and other body fluids samples.Sci Rep. 2024 Jun 12;14(1):13487. doi: 10.1038/s41598-024-63044-5. Sci Rep. 2024. PMID: 38866796 Free PMC article.
-
Discovery of p-Trifluoromethylbenzohydrazide Derivatives as Potent Antiviral Agents against Monkeypox Virus.ACS Med Chem Lett. 2025 Apr 7;16(5):837-843. doi: 10.1021/acsmedchemlett.5c00075. eCollection 2025 May 8. ACS Med Chem Lett. 2025. PMID: 40365392